drugset / Trial / NCT00343707

PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients

NCT00343707

Phase 2 Completed 72 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in Seasonal Effective Disorder (SAD) patients, using functional brain imaging readouts (i.e., WAT(Wave Analysis Technology) PET(Positron Emission Tomography)), after one or eight weeks of treatment. The effect of paroxetine alone after one or eight weeks of treatment will also be measured.

Timeline

Start
2004-11
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule
Subject Vestipitant Small molecule

Indications